Medexus Pharmaceuticals Inc. MDP.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · medexus.com
Medexus Pharmaceuticals Inc. is a Toronto-based specialty pharmaceutical company with a fully integrated North American commercial infrastructure, focused on orphan drugs and rare diseases in the therapeutic areas of rheumatology, auto-immune disease, specialty oncology, allergy, and pediatric diseases. The company commercializes specialty drugs in both Canada and the United States through its Medexus Pharma Canada and Medexus Pharma USA divisions.
Key ratios
FreeCashFlowOnSale TTM 0.17
FreeCashFlowOnSale 2025 0.22
FreeCashFlowOnSale 2024 0.17
FreeCashFlowOnSale 2023 -0.01
NetIncomeMargin TTM -0
NetIncomeMargin 2025 0.02
NetIncomeMargin 2024 -0
NetIncomeMargin 2023 0.01
ReturnOnAssets TTM 0.02
ReturnOnAssets 2025 0.05
ReturnOnAssets 2024 0.05
ReturnOnAssets 2023 0.04
ReturnOnEquity TTM -0.01
ReturnOnEquity 2025 0.05
ReturnOnEquity 2024 -0.01
ReturnOnEquity 2023 0.06
Recent news
Medexus Schedules First Fiscal Quarter 2027 Conference Call
2026-07-30 · Newsfile
Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
2026-06-25 · Medexus Pharmaceuticals
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
2026-06-16 · Medexus Pharmaceuticals
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
2026-06-09 · Medexus Pharmaceuticals